BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26462439)

  • 1. Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
    Jan AS; Dolan DE; Lombardi K; Gupta S
    Clin Genitourin Cancer; 2016 Jun; 14(3):e257-63. PubMed ID: 26462439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
    J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
    Kondo M; Hotta Y; Ando R; Yasui T; Kimura K
    Cancer Chemother Pharmacol; 2017 May; 79(5):995-1001. PubMed ID: 28391352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
    Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
    Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
    Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
    Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature.
    Gunaratne DA; Krieger LE; Maclean F; Vaux KJ; Chalasani V
    Clin Genitourin Cancer; 2016 Feb; 14(1):e103-5. PubMed ID: 26431887
    [No Abstract]   [Full Text] [Related]  

  • 10. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
    Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
    Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
    Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G
    Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
    Jin JO; Lehmann J; Taxy J; Huo D; Stöckle M; Vogelzang NJ; Steinberg G; Stadler WM
    Clin Genitourin Cancer; 2006 Sep; 5(2):150-4. PubMed ID: 17026804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
    Pal SK; Frankel PH; Mortazavi A; Milowsky M; Vaishampayan U; Parikh M; Lyou Y; Weng P; Parikh R; Teply B; Dreicer R; Emamekhoo H; Michaelson D; Hoimes C; Zhang T; Srinivas S; Kim WY; Cui Y; Newman E; Lara PN
    JAMA Oncol; 2021 Oct; 7(10):1536-1543. PubMed ID: 34436521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine Plus Cisplatin Split
    Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
    In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
    Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
    Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
    Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
    Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.